Ping Shao

The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia

Jing-ping Zhao, Jing Huang, Ranran Li, 2021, Frontiers in Human Neuroscience.

PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients

Jingping Zhao, R. Wu, Jing Huang, 2022, Psychopharmacology.

Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

J. Ou, R. Wu, K. Gao, 2016, Molecular Psychiatry.

[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].

Jingping Zhao, J. Ou, R. Wu, 2013, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

Association between olanzapine concentration and metabolic dysfunction in drug-naive and chronic patients: similarities and differences

R. Wu, R. Wu, D. Kang, 2022, Schizophrenia.

Diagnostic Stability in Psychiatric Patients From Hospital Admission to Discharge: A 10-Year Retrospective Study

R. Wu, Meiqi Yan, Menghui Gao, 2023, Psychiatry investigation.

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.

Jing-ping Zhao, Jindong Chen, R. Wu, 2008, JAMA.

Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.

E. Twamley, Jing-ping Zhao, John M. Davis, 2012, The American journal of psychiatry.